Rinvoq Bests Dupixent in Itch and Skin Clearance in Head-to-Head AD Trial
Upadacitinib (Rinvoq, AbbVie) bested dupilumab (Dupixent, Sanofi and Regeneron Pharmaceuticals, Inc.) in adults and adolescents with moderate-to-severe atopic dermatitis (AD) who had an inadequate response to or couldn’t tolerate systemic therapy, according to LEVEL UP, an open-label, head-to-head Phase 3b/4 study. The LEVEL UP study is the first head-to-head trial in atopic dermatitis assessing upadacitinib at a […]